Tesaro announced the launch of Zejula (niraparib), an oral therapy for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Zejula is a poly(ADP-ribose) polymerase (PARP) inhibitor that was initially approved by the Food and Drug Administration (FDA) in March 2017. It is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial. More studies of Zejula in ovarian, breast, and lung cancers are in the works to assess the effect of Zejula monotherapy and in combination with other therapies in different treatment settings.
Zejula is an inhibitor of PARP enzymes, PARP-1 and PARP-2, which play a role in DNA repair. Zejula-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death.
Zejula is available as 100mg strength capsules in 90-count bottles.
For more information call (844) 483-7276 or visit Zejula.com.